drugset / Trial / NCT00488384
Acitretin Plasma Levels Under Hemodialysis
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
Timeline
- Start
- 2007-06
- Primary completion
- 2014-12
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acitretin | Small molecule | 25 mg | — |